Biosimilars Stocks and Leader (Korea)
The Biosimilars theme has 10 member stock(s) today, with an average return of -1.7%. The leading stock is 삼성바이오로직스 (+5.1%, trading value 124,768,781,500).
Biosimilars are follow-on biological products approved as highly similar in efficacy and safety to reference (original) biologics, offered at lower prices after patent expiration. This theme includes biosimilar developers, distributors, and contract manufacturing organizations (CMOs), meaning pipelines and regulatory approval stages differ across individual stocks.
Approval and launch schedules, as well as overseas market share, vary widely by stock and take time to reflect in actual revenue; thus, on volatile trading days, it is important to distinguish individual company developments from sector-wide movements. The leading stock on this page is based on daily price performance and does not guarantee the scale of biosimilar operations. Comparing overlapping stocks in the Bio/Pharma theme provides additional market context.
| Stock | Price | Return | Trading Value |
|---|---|---|---|
| 삼성바이오로직스 | 1,436,000 | +5.1% | 124,768,781,500 |
| 셀트리온 | 191,600 | +1.2% | 84,396,284,150 |
| 동아에스티 | 33,900 | -0.3% | 316,648,900 |
| 셀트리온제약 | 36,600 | -0.5% | 1,293,005,925 |
| 이수앱지스 | 3,425 | -1.9% | 174,379,912 |
| 삼천당제약 | 182,900 | -3.0% | 13,101,571,450 |
| 에이프로젠바이오로직스 | 1,337 | -3.1% | 122,984,820 |
| 에이프로젠 | 1,836 | -3.2% | 231,471,024 |
| 프레스티지바이오로직스 | 1,143 | -4.2% | 217,320,602 |
| 팬젠 | 4,295 | -6.8% | 87,809,325 |
This page's data is for reference only and is not investment advice. Actual market data may differ.